Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126485691 | 12648569 | 1 | I | 20160802 | 20160812 | 20160812 | EXP | SE-PFIZER INC-2016373075 | PFIZER | PAUL, C.. A RANDOMIZED COMPARISON OF DOXORUBICIN AND DOXORUBICIN-DNA IN THE TREATMENT OF ACUTE NONLYMPHOBLASTIC LEUKEMIA. LEUKEMIA AND LYMPHOMA. 1991;3(5-6):355-364 | 0.00 | Y | 0.00000 | 20160812 | OT | SE | SE |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126485691 | 12648569 | 1 | PS | CYTARABINE. | CYTARABINE | 1 | Intravenous (not otherwise specified) | 200 MG/M2, UNK, (DURING 6 H ON DAYS 1-5) | U | 71868 | 200 | MG/M**2 | |||||||
126485691 | 12648569 | 2 | SS | CYTARABINE. | CYTARABINE | 1 | Intravenous (not otherwise specified) | 200 MG/M2, UNK,(COURSES 9-12 ON DAYS 1-5) | U | 71868 | 200 | MG/M**2 | |||||||
126485691 | 12648569 | 3 | SS | DOXORUBICIN HCL | DOXORUBICIN HYDROCHLORIDE | 1 | Intravenous (not otherwise specified) | 45 MG/M2, UNK, (COURSES 1-4 ON DAY 1) | U | 50467 | 45 | MG/M**2 | |||||||
126485691 | 12648569 | 4 | SS | DOXORUBICIN HCL | DOXORUBICIN HYDROCHLORIDE | 1 | 30 MG/M2, UNK, (COURSES 5-8 ON DAY 1) | U | 50467 | 30 | MG/M**2 | ||||||||
126485691 | 12648569 | 5 | SS | Thioguanine | THIOGUANINE | 1 | UNK | U | 0 | ||||||||||
126485691 | 12648569 | 6 | SS | AZACITIDINE. | AZACITIDINE | 1 | Intravenous (not otherwise specified) | UNK | U | 0 | |||||||||
126485691 | 12648569 | 7 | SS | AZACITIDINE. | AZACITIDINE | 1 | Intravenous (not otherwise specified) | 150 MG/M2, UNK,(DURING 3 H ON DAYS 1-5) | U | 0 | 150 | MG/M**2 | |||||||
126485691 | 12648569 | 8 | SS | AMSACRINE | AMSACRINE | 1 | Intravenous drip | 90 MG/M2, UNK, (COURSES 13-16 ON DAYS 1-5) | U | 0 | 90 | MG/M**2 |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
126485691 | 12648569 | 1 | Acute myeloid leukaemia |
126485691 | 12648569 | 3 | Acute myeloid leukaemia |
126485691 | 12648569 | 5 | Acute myeloid leukaemia |
126485691 | 12648569 | 6 | Acute myeloid leukaemia |
126485691 | 12648569 | 8 | Acute myeloid leukaemia |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
126485691 | 12648569 | DE |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
126485691 | 12648569 | Sepsis |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
no results found |